Abstract

Clonidine, idazoxan, and related imidazoline adrenergic drugs bind to non-adrenergic sites in brain and several peripheral tissues. These sites, termed imidazoline receptors, appear to exist in two major subclasses, I 1 sites labeled by clonidine and I 2 sites labeled by idazoxan. In this study, we investigated whether rat prostate expresses imidazoline receptors and, if so, whether their expression can be regulated by circulating testosterone. Studies in rat ventral prostate membrane revealed that [ 3H]idazoxan, but not [ 3H]p- aminoclonidine , bound to non-adrenergic sites. The binding of [ 3H]idazoxan was saturable ( B max: 941 ± 105 fmol/mg protein) and high affinity ( K D : 16.4 ± 2.3 nM). The rank order of the inhibition of binding by imidazoline ligands was cirazoline > clonidine > UK 14,304 > guanabenz, indicating an I 2 subclass of imidazoline receptors. Bilateral orchiectomy increased the number of binding sites ( B max) for [ 3H]idazoxan without changing the affinity ( K D ). Testosterone replacement, while completely restoring the plasma testosterone levels, only partially reversed the increase in B max. In contrast, the binding of [ 3H] idazoxan to prostate membranes of rats in different age groups (4, 7, and 16 months) revealed a progressive decrease in the B max without any change in K D . We conclude that the rat prostate expresses the I 2 subclass of imidazoline receptors and that the expression is regulated by circulating testosterone.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.